Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The drugs manufacturer, Eli Lilly, offers the medication at a list price of $1,086.37 per monthly fill (four pens for a 28-day supply)
Only the sponsor's validated data can confirm both microbiological and chemical in-use stability for a specific IMP formulation
The most commonly reported adverse effects in Phase 2 trials were gastrointestinal in nature, including: Nausea (the most frequently reported) Vomiting Diarrhoea Constipation Decreased appetite These effects were generally dose-dependent and most pronounced during dose escalation, typically improving over time
We compared the SNP effect among people treated with semaglutide versus tirzepatide (Extended Data Fig
US$ 24.61
US$ 22.06
US$ 20.14
US$ 28.64
US$ 27.10
US$ 25.29
